You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Histone deacetylase inhibitor (IC50 = 100 nM). Induces terminal cell differentiation and causes an increase in hyperacetylated histone H4. Antiproliferative agent; suppresses the growth of human endometrial and ovarian cancer cells by inducing cell cycle arrest and apoptosis.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 307.39. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.25 mL||16.27 mL||32.53 mL|
|5 mM||0.65 mL||3.25 mL||6.51 mL|
|10 mM||0.33 mL||1.63 mL||3.25 mL|
|50 mM||0.07 mL||0.33 mL||0.65 mL|
References are publications that support the biological activity of the product.
Jung et al (1999) Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J.Med.Chem. 42 4669 PMID: 10579829
Takai et al (2006) M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells. Gynecol.Oncol. 101 108 PMID: 16263156
Riessland et al (2006) The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum.Genet. 120 101 PMID: 16724231
If you know of a relevant reference for M 344, please let us know.
View Related Products by Product Action
Keywords: M 344, M 344 supplier, Histone, deacetylases, inhibitors, inhibits, HDAC, M344, epigenetics, Non-selective, HDACs, Non-Selective, 2771, Tocris Bioscience
Citations for M 344
Citations are publications that use Tocris products.
Currently there are no citations for M 344. Do you know of a great paper that uses M 344 from Tocris? Please let us know.
Reviews for M 344
There are currently no reviews for this product. Be the first to review M 344 and earn rewards!
Have you used M 344?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics Research Bulletin
Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:
- DNA Methyltransferases
- Histone Deacetylases
- Histone Demethylases
- Histone Methyltransferases
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.